Alivus Life Sciences Ltd · NSE:ALIVUS

Alivus Life Sciences — Glenmark Life Sciences — Q2 FY22 Earnings Presentation

19 slides from Alivus Life Sciences's earnings presentation, November 2021

  1. Slide 1: Q2 FY22 Investor Presentation

    Q2 FY22 Investor Presentation Glenmark Life Sciences Ltd

  2. Slide 2: Financial Performance Review

    01 Financial Performance Review

  3. Slide 3: Q2 FY22 – Highlights

    Q2 FY22 – Highlights • YoY Revenue grew at 7.9% in Q2 and Dr. Yasir Rawjee Revenue Managing Director 18.4% in H1 INR 5,618 mn and Chief • CDMO business rebound growing at Executive Officer 85.1% in Q2 and 25.2% in H1 • Continue to witness strong growth momentum in LATAM, North America At Glenmark Li

  4. Slide 4: P&L Highlights – Q2 FY22

    P&L Highlights – Q2 FY22 Amounts in INR Millions Q2 FY22 Q1 FY22 QoQ Q2 FY21 YoY H1 FY22 H1 FY21 YoY Revenue from Operations 5,617.6 5,249.0 7.0% 5,208.1 7.9% 10,866.6 9,177.7 18.4% Gross Profit 2,905.4 2,655.2 9.4% 2,268.3 28.1% 5,560.7 4,483.6 24.0% Gross Profit (%) 51.7% 50.6% 43.6% 51.2% 48.9% O

  5. Slide 5: Key Balance Sheet Items and Cash flow

    Key Balance Sheet Items and Cash flow Key Balance Sheet Items Free Cash Flow As at 30th As at 31st Amounts in INR Millions H1 FY22 H1 FY21 FY21 Amounts in INR Millions Sep'21 Mar'21 Profit Before Tax 2,875.0 2,051.3 4,709.4 Equity 19,780.0 7,527.5 Adjustment for Non Operating Items* 510.1 680.6 1,33

  6. Slide 6: Quarter on Quarter Performance

    Quarter on Quarter Performance Sustained growth momentum and improving PAT margins after debt pay-down 36.4% 30.2% 37 . 0% 5,618 31.3% 31.0% 5,208 5,249 32 . 0% 5,002 4,672 1,500 24.4% 27 . 0% 22 . 0% 17 . 0% 1,702 1,644 1,694 1,000 1,552 12 . 0% 1,269 7.0% 2.0% 500 -3. 0 % Revenue Q2 FY21 Q3 FY21 Q

  7. Slide 7: Financial Performance Track Record

    Financial Performance Track Record Robust growth trajectory with healthy profitability indicators 18,852 35 . 0% 31.5% 31.4% 30.7% 6,000 30.6% 15,373 30 . 0% 14,050 5,000 27.6% 12,017 10,867 25 . 0% 4,000 5,919 20 . 0% 4,840 3,000 4,298 2,000 3,317 3,339 15 . 0% Revenue 1,000 10 . 0% FY18 FY19 FY20

  8. Slide 8: Strong Returns Indicators

    Strong Returns Indicators ROCE Fixed Assets Turnover Working Capital Days 33% 3.7 FY19 FY20 FY21 H1 FY22 33% 3.3 350 250 32% 300 202 2.9 173 176 200 31% 2.7 250 159 31% 2.5 150 200 98 150 104 99 85 100 100 50 152 120 50 116 115 - - - 50 -47 -48 -43 -42 - 50 AR Days AP Days FY18 FY19 FY20 FY21 H1 FY2

  9. Slide 9: Business Performance Review

    02 Business Performance Review

  10. Slide 10: Segment Performance

    Segment Performance 3.9% YoY 5.1% QoQ 85.1% YoY 26.1% QoQ 5,047 4,858 4,803 Revenue (₹ Mn) 4,675 Revenue (₹ Mn) 4,078 548 490 389 265 280 Generic API Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 CDMO Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 • Generic API revenues in Q2FY22 • CDMO revenues registered stron

  11. Slide 11: Market and Therapeutic Area Mix

    Market and Therapeutic Area Mix 24% 27% 27% 33% 40% 37% 37% 43% 37% 45% 5% 6% 4% 4% 3% 8% 14% 3% 6% 7% 4% 7% 10% 14% 8% 76% 73% 63% 67% 60% 44% 47% 37% 40% 39% Market Therapeutic Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 Mix Area Mix Regulated Markets Emerging M

  12. Slide 12: Company Overview

    03 Company Overview 6G clenmark LIFE SCIENCES

  13. Slide 13: Global Footprint

    Global Footprint Filed 412 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 50+ 330+ 30+ 81 112 143 10+ 16 100+ 50+ 60 (Brazil) India – Mix of Regulated Number of Number of customers Regulated Markets Emerging Mark

  14. Slide 14: Quality-focused, compliant manufacturing & R&D infrastructure

    Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity (Mar-21) Last USFDA Inspection Date Approvals Mahape, Navi Mumbai USFDA, MHRA (UK), FIMEA  R&D for new product development (Finland), Romania (Europe) and complex

  15. Slide 15: R&D Capabilities

    R&D Capabilities 450 5.0% 400 405 400 376 4.5% Cumulative Filing Status 350 4.0% 300 275 3.5% North Therapy Europe Japan Brazil ROW Total 250 2.7% 2.6% 3.0% America 2.5% 200 2.1% 2.5% CVS 34 27 4 15 34 114 150 2.0% CNS 34 16 7 12 11 80 100 1.5% Diabetes 9 3 - 7 9 28 50 1.0% Pain Management - 2 - 3 9

  16. Slide 16: Strategy Going Forward

    04 Strategy Going Forward 6G clenmark LIFE SCIENCES

  17. Slide 17: Strategic Growth Levers

    Strategic Growth Levers • New product launches • Ramp up CDMO portfolio • Geographical expansion • Expand into complex API platforms • Focus on new markets becoming more • Iron compounds regulated • Oncology • Pursue 2nd source opportunities with top generic players Gx API New Growth Business levers

  18. Slide 18: Future Capacity Expansion Plan

    Future Capacity Expansion Plan Current Status & Planned Operational Expansion Type Division Location Capacity Capacity Timelines Under Construction Phase I – Q4FY22 Brownfield API Dahej 141.9 KL 4 Modules -240 KL Phase II – Q2 FY23 New plant Brownfield Intermediate Ankleshwar 550.2 KL Q2 FY23 400 KL

  19. Slide 19: Thank You

    Thank You Glenmark Life Sciences Limited Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. T: 91 22 68297979 CIN: U74900PN2011PLC13996

Glenmark Life Sciences — Q2 FY22 Earnings Presentation on 6ix